Literature DB >> 6218862

Long term consequences of arsenical treatment for multiple sclerosis.

D A Robertson, T S Low-Beer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6218862      PMCID： PMC1546829          DOI： 10.1136/bmj.286.6365.605-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  2 in total

1.  Arsenic and noncirrhotic portal hypertension.

Authors:  J S Morris; M Schmid; S Newman; P J Scheuer; S Sherlock
Journal:  Gastroenterology       Date:  1974-01       Impact factor: 22.682

2.  Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India.

Authors:  D V Datta; S K Mitra; P N Chhuttani; R N Chakravarti
Journal:  Gut       Date:  1979-05       Impact factor: 23.059
  2 in total
  2 in total

1.  Multiple sclerosis incidence associated with the soil lead and arsenic concentrations in Taiwan.

Authors:  Ching-Piao Tsai; Charles Tzu-Chi Lee
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

2.  Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice by inducing CD4+ T cell apoptosis.

Authors:  Ke An; Meng-Jiao Xue; Jia-Ying Zhong; Sheng-Nan Yu; Tian-Shu Lan; Zhong-Quan Qi; Jun-Jie Xia
Journal:  J Neuroinflammation       Date:  2020-05-06       Impact factor: 8.322
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.